3 mAbs (hematological malignancies and/or solid tumors)
New humanized monoclonal antibodies (mAbs), against newly identified antigen oncology targets, acting through Antibody Dependent Cell Cytotoxicity (ADCC) or as Antibody Drug Conjugated (ADC-antibody linked to a toxin) will be developed.
Selective and high affinity mAbs are being generated by an external partner.
Characterization of these mAbs in terms of binding characteristics, in vitro efficacy (ADCC, cytotoxicity, internalization), in vivo efficacy (xenograft models) and exploratory toxicology are ongoing.
Menarini will be responsible for: (i) development and commercial manufacturing, (ii) regulatory non-clinical development, (iii) clinical development phase I to phase III and (iv) regulatory submission to main Regulatory Agencies.
According to the agreement with OBT for the development and commercialization of 5 Antibodies, 2 of them are in Phase I clinical trial (MEN1112) and Preclinical development (MEN1309)
Press Release 29/10/2012